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ABSTRACT
Introduction: Rheumatic heart disease (RHD) is a
chronic disease affecting the heart valves, secondary to
group A streptococcal infection (GAS) and subsequent
acute rheumatic fever (ARF). However, RHD cure and
preventative measures are inextricably linked with
socioeconomic development, as the disease mainly
affects children and young adults living in poverty. In
order to address RHD, public health officials and
health policymakers require up-to-date knowledge on
the epidemiology of GAS, ARF and RHD, as well as the
existing enablers and gaps in delivery of evidence-
based care for these conditions. We propose to
conduct a systematic review to assess the literature
comprehensively, synthesising all existing quantitative
and qualitative data relating to RHD in Africa.
Methods and analysis: We plan to conduct a
comprehensive literature search using a number of
databases and reference lists of relevant articles
published from January 1995 to December 2015. Two
evaluators will independently review and extract data from
each article. Additionally, we will assess overall study
quality and risk of bias, using the Newcastle-Ottawa Scale
and the Critical Appraisal Skills Programme criteria for
quantitative and qualitative studies, respectively. We will
meta-analyse estimates of prevalence, incidence, case
fatality and mortality for each of the conditions separately
for each country. Qualitative meta-analysis will be
conducted for facilitators and barriers in RHD health
access. Lastly, we will create a list of key stakeholders.
This protocol is registered in the PROSPERO
International Prospective Register of systematic reviews,
registration number CRD42016032852.
Ethics and dissemination: The information provided
by this review will inform and assist relevant stakeholders
in identifying key areas of intervention, and designing and
implementing evidence-based programmes and policies
at the local and regional level. With slight modifications
(ie, to the country terms in the search strategy), this
protocol can be used as part of a needs assessment in
any endemic country.
INTRODUCTION
Background
Rheumatic heart disease (RHD) is a chronic
inﬂammatory disease of the heart valves that
usually results from recurrent episodes of
acute rheumatic fever (ARF). ARF results
from untreated Group A streptococcal (GAS)
throat infection (pharyngitis).1–3 The clinical
signs and symptoms of RHD typically present
between the ages of 20 and 50 years.1 This
clinical period is preceded by a long latent
period. RHD tends to be more prevalent in
women than in men. In many cases, its ﬁrst
manifestation is during pregnancy, when
physiological stress on the heart increases,
and this increases the risk of poor fetal and
Strengths and limitations of this study
▪ The review implements a wide range of methods
and data to comprehensively and accurately
describe rheumatic heart disease (RHD) in
Africa, taking into consideration the epidemi-
ology, health systems constraints and stake-
holders involved.
▪ The data will be systematically and rigorously
assessed using the most recently published
standard quality assessment tools for different
study designs. The data ensuing from this review
will ultimately inform healthcare policy around
RHD in Africa.
▪ By casting a broad net, we will need to manage
a wide variety of literature from different disci-
plines. We anticipate that reports from non-
governmental organisations and ministry of
health documents will be important sources of
information for public health planning, so that a
broader more inclusive approach can be used for
these data without the need for stringent criteria,
for example, for systematic reviews of clinical
trials.
▪ There will be significant heterogeneity in the
case definitions, which may limit our ability to
draw conclusions from the data, particularly
objective conclusions.
▪ The methods for systematic reviews of qualitative
research are less well developed, so our analytic
approach will be focused on ‘broad strokes’ and
common themes rather than nuanced ethno-
graphic analysis.
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maternal outcomes.1 It is estimated that RHD is respon-
sible for 233 000–294 000 deaths globally each year.4
Primary preventative measures focus on treating GAS
pharyngitis with benzathine penicillin in order to
prevent ARF.1 Secondary prevention measures focus on
treating individuals with a history of ARF or RHD, using
penicillin as prophylaxis against recurrent ARF and pro-
gression of RHD. Guidelines for primary and secondary
prevention regimes differ between country and region.
Individuals with symptomatic RHD may require a variety
of medical or surgical interventions for repair, replace-
ment or palliation of damaged valves.1 However, the
latent period of RHD poses signiﬁcant barriers to clin-
ical screening and preventative treatment because indivi-
duals are asymptomatic; in fact, up to 50% of individuals
with RHD do not recall an episode of ARF in child-
hood.5 Furthermore, many patients ﬁrst present to care
with advanced heart failure or with other complications,
such as infective endocarditis or stroke due to atrial
ﬁbrillation.1
In low and middle-income countries (LMIC), RHD
treatment and prevention is further complicated by lack
of access to these interventions at different levels of
care. Barriers to healthcare access include: limited com-
munity awareness, inadequate health literacy, inadequate
health-seeking behaviour and lack of available, afford-
able and acceptable treatment options.6 These fre-
quently occur in the context of a public health and
policy environment that does not adequately recognise
and does not devote resources to RHD.7 At the same
time, RHD treatment and prevention measures are inex-
tricably linked with economic status and social develop-
ment: the disease was largely eradicated during the
latter 20th century, in high-income countries.8 On the
contrary, in LMICs, and especially in African nations,
RHD remains the most common cause of acquired heart
disease, mostly affecting children and young adults living
in poverty.4 9
In order to address RHD, public health ofﬁcials and
health policymakers require information about the epi-
demiology of GAS, ARF and RHD. They also require spe-
ciﬁc contextual information about local, regional and
national healthcare delivery patterns, and the various
stakeholders who would be involved in programmes and
policies to prevent and control RHD. This information is
particularly important in African nations where RHD
continues at a high rate, and resources for adequate pre-
vention and control are especially scarce.
We propose to conduct a systematic review to assess
the literature comprehensively, synthesising all existing
quantitative and qualitative data concerning the epi-
demiology of RHD and related health system factors in
African nations. We will combine a wide range of
methods—further described in the data synthesis
section—to paint a complete picture of the current state
of RHD disease burden and clinical care. This scientiﬁc
question by its nature makes our review different from a
traditional systematic review.10 11
Objectives
Our systematic review has three objectives: (1) to quan-
tify the burden of RHD, ARF and GAS in African coun-
tries; (2) to describe the patient and provider
experience with GAS, ARF and RHD care within health-
care systems in these countries; and (3) to identify the
types of stakeholders who currently are, or need to be,
engaged when designing and implementing RHD pro-
grammes in African settings. These objectives are listed
in table 1.
METHODS AND ANALYSIS
This review protocol has been published in the
PROSPERO International Prospective Register of system-
atic reviews (http://www.crd.york.ac.uk/PROSPERO),
registration number CRD42016032852. A Preferred
Reporting Items for Systematic review and Meta-Analysis
Protocols checklist has been completed and included as
online supplementary material.
Inclusion criteria
We will include study articles—published from January
1995 to December 2015—that satisfy the following cri-
teria as appropriate to each of the speciﬁed objectives:
Types of studies
Objective 1: case series, cross sectional studies and
cohort studies (retrospective or prospective).
Objective 2: phenomenological and ethnographic (quali-
tative) studies, including both individual in-depth inter-
views and focus group discussions.
Objective 3: studies that employ single or mixed
methods combining any of the above study designs. We
will also consider case reports of RHD programmes or
policies in which stakeholders were identiﬁed and
leveraged.
Types of study subjects
Objective 1: individuals who reside in geographic
regions conﬁned to the African continent.
Objective 2: individuals who utilise or provide RHD
healthcare within health systems in African
communities.
Table 1 Objectives
Objective 1 To quantify the burden of RHD, ARF and
GAS in African countries
Objective 2 To describe the patient and provider
experience with GAS, ARF and RHD care
within healthcare systems in these countries
Objective 3 To identify the types of stakeholders who
currently are, or need to be, engaged when
designing and implementing RHD
programmes in African settings
ARF, acute rheumatic fever; GAS,group A streptococcal infection;
RHD, rheumatic heart disease.
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Objective 3: individuals with a vested interest in RHD
within African countries (see ‘case deﬁnitions’, below).
Case Definitions
Objective 1
Group A streptococcal pharyngitis. In a symptomatic partici-
pant, GAS can be deﬁned through the use of a clinical
predictor rule such as the Walsh pharyngitis criteria,
McIsaac decision rule and Centor criteria.12–14
Alternatively, a microbiological test such as a throat
culture or a rapid antigen test can conﬁrm the presence
of GAS in the pharynx of a participant.12 To allow for
local experiences with GAS and its sequelae, we will note
the case deﬁnition used in each study and handle any
heterogeneity due to different case deﬁnitions during
the data analysis phase.
Acute rheumatic fever. The diagnosis of the ﬁrst episode of
ARF relies on a constellation of clinical features that
follow the Jones criteria (1992) and its subsequent revi-
sions.15 We will use these criteria as our ARF case deﬁn-
ition in this review, rather than the 2015 revision, as
these are still being introduced into standard of care.16
Rheumatic heart disease. Prevalence of RHD has in the
recent past been deﬁned by screening programmes of
subclinical disease in asymptomatic populations, using
different criteria. These criteria include those proposed
by WHO in 2001, the World Heart Federation in 2012 and
authors’ criteria adapted for particular screening
studies.17–19 Hospital-based studies, however, focus on clin-
ical disease in symptomatic populations. As far as possible,
we will elucidate the diagnostic methods in either echocar-
diography screening studies or hospital-based studies.
We will adopt two case deﬁnitions for RHD (RHD as
diagnosed by a clinician with echocardiographic con-
ﬁrmation or RHD with echocardiographic conﬁrmation
only) and explore statistically the impact of different
diagnostic criteria on estimates of RHD prevalence.
Objective 2
We anticipate some variation in case deﬁnitions in
studies of healthcare delivery. As we are not attempting
to estimate population health but rather describe prac-
tices around healthcare, we will consider all studies in
which participants have been clinically diagnosed with
GAS, ARF or RHD. The case deﬁnition used in the
study will be recorded during the data extraction phase
and will be discussed in the analysis if it is deemed to
have a substantial impact on interpretation.
Objective 3
In this study, we will deﬁne stakeholders as groups or
individuals who have an interest, ﬁnancial or otherwise,
in the implementation or outcomes of healthcare pol-
icies, services, practices, processes and/or decisions.20
We will consider any studies that clearly deﬁne stake-
holders involved in any aspect of GAS, ARF and RHD.
Types of outcome measures
Objective 1
We will seek estimates of one or more of the following
epidemiological parameters:
GAS: incidence of GAS pharyngitis and prevalence of
GAS among cases of sore throat.
ARF: incidence of ARF and case-fatality rate from ARF.
RHD: incidence of RHD, prevalence of RHD, excess
mortality from RHD, case-fatality rate from RHD and
rates of non-fatal outcomes such as heart failure, stroke,
infective endocarditis, atrial ﬁbrillation and cardiac
surgery and its complications.
Objective 2
We will seek descriptions of RHD healthcare utilisation
patterns, speciﬁcally barriers and facilitators that may
occur along a care pathway. Table 2 presents a concep-
tual model of the potential barriers and facilitators
along this continuum incorporating ‘supply’ (providers
and systems) and ‘demand’ (patients).
Objective 3
We will identify and characterise stakeholders and deter-
mine inter-relationships as described in the included
studies. In the event that we do not ﬁnd any studies of
stakeholders per se, we will utilise the authors and afﬁlia-
tions of the studies from objective 1 and 2 to record
information on the various RHD stakeholders identiﬁed
by the authors of the included studies.
Exclusion criteria
Opinion, case reports and narrative reviews will be
excluded. Systematic reviews will be retained temporarily
to manually search reference lists, but ultimately
excluded. Publications lacking primary data and/or
adequate descriptions of methods will be excluded.
Furthermore, if any study has been published in more
than one journal/conference, we will exclude all but the
most complete and recent version of the data set in
question. All unpublished studies must have ethics
approval to be considered.
Importantly, we will exclude studies published prior to
1995. The rationale for this date restriction is that we are
seeking contemporary information on RHD, to inform
Table 2 Barrier and facilitators matrix
Patients
Health
providers
Health
Systems
Initial decision to seek
care
✓ ✓ ✓
Factors influencing
diagnosis
✓ ✓ ✓
Factors influencing
treatment and/or referral
✓ ✓ ✓
Factors influencing
adherence and retention
in long-term care
✓ ✓ ✓
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programme development. We also note that echocardi-
ography has only been widely used for diagnosis and
screening of RHD in the past two decades.
We anticipate that reports from non-governmental
organisations and ministry of health documents will be
important sources of information for public health plan-
ning, so that a broader and more inclusive approach will
be used to review these data.
Search strategy and process
We have developed a comprehensive search strategy that
incorporates a combination of free term text items and
Medical Subject Headings (MESH) terms. In addition,
to maximise the likelihood of ﬁnding articles from
Africa, we have applied an Africa-speciﬁc search ﬁlter
described previously by Pienaar et al.21 Their search strat-
egy was appropriately modiﬁed to suit the vocabulary of
individual database(s). The complete search strategy,
incorporating terms relevant to all three objectives, is
shown in tables 3 and 4 for PUBMED and EMBASE,
respectively.
Two reviewers will independently screen titles,
abstracts and full-text articles. Our primary searches will
be conducted on PUBMED, EMBASE and the Worldcat
database of dissertations. We will search conference pro-
ceedings of the Lanceﬁeld Symposia, the Pan African
Society of Cardiology, the World Congress of Cardiology
and the World Congress of Paediatric Cardiology and
Cardiac Surgery, for additional publications and
abstracts. We will also search Google Scholar. We will
contact relevant departments in the Ministries of Health
to obtain death notiﬁcation data for mortality estimates.
Also, experts and in-country university librarians in the
ﬁeld will be consulted to identify additional information
such as relevant NGO reports and other unpublished
work. Finally, the reference lists of all potentially identi-
ﬁed papers will be manually searched for possible
studies that were missed by our initial search. Search
results from individual databases, reference searches and
unpublished articles, will be imported and managed
with Covidence (2013 Covidence).
DATA EXTRACTION AND ANALYSIS
Data extraction and management
Two reviewers will independently appraise and extract
data from each full-text article. Contradictions will be
resolved through consensus. A third reviewer will act as
an arbitrator where necessary. Using a standardised data
extraction form, we will extract the following descriptive
and outcome data from each study:
▸ Study identiﬁcation: authors, year of publication.
▸ Eligibility criteria: inclusion and exclusion into the
review.
▸ Study characteristics: study design, characteristics of
study participants (ie, demographic information),
length of participation, country, study setting (rural,
urban, peri urban), number enrolled into the study.
▸ Case deﬁnition: see inclusion criteria.
▸ Details of the outcome measure: (1) GAS, ARF and
RHD epidemiology, (2) Barriers and facilitators, (3)
Stakeholders.
▸ Quality assessment: see below.
▸ Notes: general study comments.
Data synthesis and analysis
Objective 1
We will meta-analyse estimates of prevalence, incidence,
case fatality and mortality for each of the conditions.
Before any meta-analysis is conducted, heterogeneity will
be assessed by (1) visualising the overlap of CIs in forest
plots and (2) calculating the I2 statistic, with caution
taken in cases where I2 exceeds 50%.22 Inverse variance-
weighted random effects models will be used on logit-
transformed prevalence and case-fatality ratios, and on
log-transformed incidence and mortality rates. We will
also explore reasons for heterogeneity, using subgroup
analyses or random effects meta-regression on the fol-
lowing parameters: study location, year of study and case
deﬁnition. If the data are limited or cannot be pooled
due to substantial heterogeneity, the ﬁndings will be pre-
sented in narrative form.
Objective 2
We anticipate that the data relevant to the second
objective will be predominately qualitative. Qualitative
meta-analysis (meta-synthesis) aims to uncover similar-
ities and differences across individual studies, and thus
generate new insights and areas of inquiry, rather than
reduce the ﬁndings of multiple studies to a series of
pooled summary statistics.23
Data synthesis will occur in three overlapping stages.
First, we will code the ﬁndings of individual primary
studies according to their meaning and content (ie, bar-
riers and facilitators and their determinants). Second,
we will organise the ‘codes’ into related areas to con-
struct ‘descriptive’ themes.24 These will be listed in a
data display matrix based on our conceptual model
(table 1). Third, we will develop ‘analytical’ themes
based on our insights, which can then be incorporated
into an explanatory model of health-seeking behaviours
and their determinants around GAS, ARF and RHD.
We also anticipate that some studies will present
numerical estimates of barriers and facilitators, for
example, the proportion of patients with RHD not
taking secondary prophylaxis due to disease stigma. We
will extract these estimates and present them in the data
display matrix. If the number of repeated estimates and
quality of the data for any barrier or facilitator are sufﬁ-
cient, we will conduct a quantitative meta-analysis, using
methods similar to those used in objective 1.
Objective 3
We will create a list of the stakeholders, classifying them by
organisational afﬁliation, qualiﬁcation/expertise, group
represented and impact on the deliberative process. The
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Table 3 PubMed search strategy
Subject Search terms
#1 Group A β-Haemolytic Streptococcal, Acute
Rheumatic Fever, Rheumatic Heart Disease
“Pharyngitis” [Mesh] OR Pharyngitis OR Sore Throat OR Strep OR
Group A β-Hemolytic Streptococcal OR “Streptococcus Pyogenes”
[Mesh] OR Group A Streptococcus OR Group A Streptococcal
Infection OR “impetigo” [MeSH] OR impetigo OR group a
streptococcus skin infection OR Rheumatic fever OR “Rheumatic
Fever” [Mesh] OR Rheumatic heart Disease OR “Rheumatic Heart
Disease” [Mesh]
#2 Service Delivery Accessibility of health services OR Availability of health services OR
Attitudes to Health OR Barrier* OR Delivery of Health Care OR
Facilitator* OR Health OR “Health Behavior” [MeSH] OR Health Care
OR Health Care Quality, Access, and Evaluation OR “Health Care
personnel OR Health Education” [MeSH] OR Patient compliance OR
Patient education OR Professional Knowledge OR Obstacle*
#3 Stakeholder Analysis Collaboration OR Health Policy OR Mapping OR “Policy” [MeSH] OR
Policy OR Stakeholder
#4 Country africa[tw] OR africa’[tw] OR africa’s[tw] OR africa1[tw] OR africa2[tw]
OR africaans[tw] OR africacollaborations[tw] OR africae[tw] OR
africaeaustralis[tw] OR africahiv[tw] OR africaid[tw] OR africaid’s[tw]
OR africain[tw] OR africaine[tw] OR africaine’s[tw] OR africaines[tw]
OR africains[tw] OR africal[tw] OR africam[tw] OR africamum[tw] OR
african[tw] OR african’[tw] OR african”[tw] OR african’s[tw] OR
african1[tw] OR african2[tw] OR africana[tw] OR africanae[tw] OR
africanalleles[tw] OR africanamerican[tw] OR africanan[tw] OR
africanane[tw] OR africananes[tw] OR africanasian[tw] OR
africanastrongylus[tw] OR africancalotropis[tw] OR africander[tw] OR
africanders[tw] OR africane[tw] OR africanendemic[tw] OR africanene
[tw] OR africanenes[tw] OR africanensis[tw] OR africanenvironment
[tw] OR africaner[tw] OR africanes[tw] OR africani[tw] OR africanised
[tw] OR africanism[tw] OR africanist[tw] OR africanists[tw] OR
africanity[tw] OR africanium[tw] OR africanizada[tw] OR africanization
[tw] OR africanization’[tw] OR africanize[tw] OR africanized[tw] OR
africanized’[tw] OR africanizing[tw] OR africanjournal[tw] OR
africannum[tw] OR africano[tw] OR africanoides[tw] OR africanol[tw]
OR africanos[tw] OR africanoside[tw] OR africanpatients[tw] OR
africanpiper[tw] OR africans[tw] OR africans’[tw] OR africanton[tw] OR
africantrinervitermes[tw] OR africantriol[tw] OR africanum[tw] OR
africanum’[tw] OR africanumsp[tw] OR africanumt[tw] OR africanus
[tw] OR africanus’[tw] OR africanusgen[tw] OR africanz[tw] OR
africare[tw] OR africarice[tw] OR africas[tw] OR africasia[tw] OR
africative[tw]) OR Algeria[tw] OR Angola[tw] OR Benin[tw] OR
Botswana[tw] OR Burundi[tw] OR Cameroon[tw] OR Chad[tw] OR
Comoros[tw] OR Congo[tw] OR Djibouti[tw] OR Egypt[tw] OR Eritrea
[tw] OR Ethiopia[tw] OR Gabon[tw] OR Gambia[tw] OR Ghana[tw] OR
Guinea[tw] OR Jamahiriya[tw] OR Jamahiriya[tw] OR Kenya[tw] OR
Lesotho[tw] OR Liberia[tw] OR Libya[tw] OR Libya[tw] OR
Madagascar[tw] OR Malawi[tw] OR Mali[tw] OR Mauritania[tw] OR
Mauritius[tw] OR Mayotte[tw] OR Morocco[tw] OR Mozambique[tw]
OR Mozambique[tw] OR Namibia[tw] OR Niger[tw] OR Nigeria[tw] OR
Principe[tw] OR Reunion[tw] OR Rwanda[tw] OR Senegal[tw] OR
Seychelles[tw] OR Somalia[tw] OR Sudan[tw] OR Swaziland[tw] OR
Tanzania[tw] OR Togo[tw] OR Tunisia[tw] OR Uganda[tw] OR Zaire
[tw] OR Zambia[tw] OR Zimbabwe[tw]
Search #1 AND #4
Search #1 AND #2 AND #4
Search #1 AND #3 AND #4
Filters: Publication date from 01 01 1995 to 31 12 2015.
*Wildcard term as per database notation; MeSH, medical subject heading.
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ﬁndings will be displayed in spoke-and-wheel diagrams,
ﬂow charts, or narrative form, depending on the nature of
the data.
Missing data
Missing data for each study will be described and dis-
cussed as to the extent to which they could alter the
results. Where deemed necessary, the studies’ authors
will be contacted to request for missing information.
Quality appraisal of included studies
We will assess the quality of included studies to evaluate
for risk of bias related to the reliability of the estimates
of the outcome measures of the study. A high-quality
study is considered to have low risk of bias and a low
quality study is associated with higher risk of bias. Our
assessment of risk of bias will inform the evaluation of
heterogeneity in the pooled analyses, especially for
objective 1.
Objective 1
We will employ the modiﬁed version of the
Newcastle-Ottawa Scale (NOS) for quantitative observa-
tional studies (see online supplementary appendix 1).25
Brieﬂy, the NOS criteria assess cross-sectional studies,
cohort studies and case series reports on various items
categorised into three groups: the selection of the study
groups, the comparability of the groups and the ascer-
tainment of the outcome of interest.
Table 4 EMBASE search strategy
Subject Search terms
#1 Group A β-Haemolytic Streptococcal, Acute
Rheumatic Fever, Rheumatic Heart Disease
‘group a streptococcal infection’/exp OR ‘streptococcus group a’/exp
OR ‘group a streptococcal infection’ OR ‘streptococcus group a’ OR
‘pharyngitis’/exp OR ‘pharyngitis’ Sore throat OR ‘impetigo’ OR
‘impetigo’/exp OR ‘group a streptococcus skin infection’/exp OR
‘rheumatic fever’/exp OR ‘rheumatic fever’ OR ‘rheumatic heart
disease’/exp OR ‘rheumatic heart disease’
#2 Service Delivery ‘Accessibility of health services’ OR ‘Availability of health services’
OR ‘Attitudes to Health’ OR ‘Barrier’ OR ‘Delivery of Health Care’
OR ‘Facilitator’ OR ‘Health’ OR Health Behavior OR ‘Health Care’
OR ‘Health Care Quality, Access, and Evaluation’ OR ‘Health Care
personnel’ OR Health Education OR ‘Patient compliance’ OR
‘Patient education’ OR ‘Professional Knowledge’ OR ‘Obstacle’
#3 Stakeholder Analysis ‘Collaboration’ OR ‘Health Policy’ OR ‘Mapping’ OR ‘Policy’ OR
‘Stakeholder’
#4 Country ‘Africa’ OR Africa* OR Algeria OR Angola OR Benin OR Botswana
OR ‘Burkina Faso’ OR Burundi OR Cameroon OR ‘Canary Islands’
OR ‘Cape Verde’ OR ‘Central African Republic’ OR Chad OR
Comoros OR Congo OR ‘Democratic Republic of Congo’ OR Djibouti
OR Egypt OR ‘Equatorial Guinea’ OR Eritrea OR Ethiopia OR
Gabon OR Gambia OR Ghana OR Guinea OR ‘Guinea Bissau’ OR
‘Ivory Coast’ OR ‘Cote d Ivoire’ OR Jamahiriya OR Jamahiryia OR
Kenya OR Lesotho OR Liberia OR Libya OR Libia OR Madagascar
OR Malawi OR Mali OR Mauritania OR Mauritius OR Mayote OR
Morocco OR Mozambique OR Mocambique OR Namibia OR Niger
OR Nigeria OR Principe OR Reunion OR Rwanda OR ‘Sao Tome’
OR Senegal OR Seychelles OR ‘Sierra Leone’ OR Somalia OR
‘South Africa’ OR ‘St Helena’ OR Sudan OR Swaziland OR
Tanzania OR Togo OR Tunisia OR Uganda OR ‘Western Sahara’
OR Zaire OR Zambia OR Zimbabwe OR ‘Central Africa’ OR ‘Central
African’ OR ‘West Africa’ OR ‘West African’ OR ‘Western Africa’ OR
‘Western African’ OR ‘East Africa’ OR ‘East African’ OR ‘Eastern
Africa’ OR ‘Eastern African’ OR ‘North Africa’ OR ‘North African’ OR
‘Northern Africa’ OR ‘Northern African’ OR ‘South Africa’ OR ‘South
African’ OR ‘Southern Africa’ OR ‘Southern African’ OR ‘sub
Saharan Africa’ OR ‘sub Saharan African’ OR ‘subSaharan Africa’
OR ‘subSaharan African’ OR ‘guinea pig’ OR ‘guinea pigs’ OR
‘aspergillus niger’
Search #1 AND #4
Search #1 AND #2 AND #4
Search #1 AND #3 AND #4
Filters: Publication date from 01 01 1995 to 31 12 2015.
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To allow for relative comparison between the studies
and reduce reviewers’ subjectivity, we will add a quantita-
tive scoring system to the risk of bias table to categorise
studies as low risk, moderate risk and high risk.25
Objective 2
Evidence from qualitative studies will be evaluated using
the 10 criteria adapted from the Critical Appraisal Skills
Programme (see online supplementary appendix 2).26
This grading tool implements the same broad principals
of validity used for quantitative research, however, it puts
them in a framework that takes into account the differ-
ent aims and methods used in qualitative research.
DISSEMINATION
This protocol will guide a systematic review that gener-
ates three important areas of new knowledge. First, it
will quantify the contemporary burden of GAS and its
sequelae (ARF and RHD) in African settings. Second, it
will provide a situational assessment of existing barriers
and challenges around delivery of clinical care for GAS,
ARF and RHD in African communities. Third, it will
identify different stakeholders within the realm of RHD
in African countries.
The information provided by this review will inform
and assist stakeholders in identifying key areas of inter-
vention, and designing and implementing evidence-
based programmes and policies, at the local and
regional level. With slight modiﬁcations to the search
strategy, this protocol can also be used as part of a needs
assessment in any endemic country.
A unique strength of our review is that it will draw
upon a wide range of research methods and data
sources, to comprehensively and accurately describe the
opportunities for, and challenges to, RHD prevention
and control in Africa. We will systematically and rigor-
ously analyse and assess studies, using up-to-date
meta-analysis/meta-synthesis techniques and the most
recently published quality assessment tools.
Nevertheless, our review has several limitations. First,
by casting a broad net, we will need to manage a wide
variety of literature from different disciplines. We antici-
pate that lower-quality studies will be important sources
of information for public health planning, so we will
have to relax the usual stringent criteria used, for
example, for systematic reviews of clinical trials. Second,
we recognise that signiﬁcant heterogeneity in the case
deﬁnitions may limit our ability to draw conclusions
from the data, particularly for objective 1. Third, the
methods for systematic reviews of qualitative research are
less well developed, so our analytic approach will be
focused on ‘broad strokes’ and common themes rather
than nuanced ethnographic analysis.
In summary, we anticipate that this review will provide
comprehensive data on the epidemiology of GAS, ARF
and RHD in African settings, with the additional lens of
health systems and stakeholders. These data will inform
key areas of intervention for research, practice and
policy in endemic RHD countries.
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